We further interrogated the association of PRR11 expression with response to estrogen suppression in two other clinical studies of ER+ breast cancers treated with a neoadjuvant aromatase inhibitor (Supplementary Table 1; cohort of Giltnane et al.14; cohort of Miller et al.22). Here, PRR11 is linked to breast carcinoma.